CDH2 and prostate cancer: Studies have shown pimozide's effectiveness in inhibiting epithelial‐mesenchymal transition and migration invasion in prostate cancer and hepatocellular carcinoma by downregulating N‐cadherin expression and upregulating E‐cadherin expression.47, 48